A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Phase 3 Terminated 98 enrolled Ortho Biotech Products, L.P.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of PROCRIT (Epoetin alfa) administered at 40,000 Units weekly in cancer patients that are not receiving chemotherapy or radiation therapy.

Timeline

Start: 2002-09
Primary completion: —
Completion: 2004-03

Outcome

Outcome not reported

Stopped (Enrollment): “This study was stopped early due to slow enrollment.”

Publications

Results Shasha D, Williams D. Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy. J Support Oncol. 2006 Mar;4(3):129-35.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	epoetin alfa	Protein / enzyme biologic	40000 iu	Subcutaneous